Evolva Holding, Serodus A/S deal

Evolva granted Serodus an option to acquire exclusive, worldwide rights EV-077 to treat diabetic nephropathy. The option is exercisable by Dec. 31. Serodus said it plans to start a Phase II trial evaluating EV-077 in mid-2014. If the option is exercised, Evolva would be eligible to receive clinical and regulatory milestones and single-digit royalties. If Serodus out-licenses the compound, Evolva would also receive up to 30% of Serodus' total licensing income. ...